Experts Discuss Unique Challenges Posed by Difficult-to-Treat RA

Vanessa Caceres is a medical writer in Bradenton, Fla.

References

1. Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study. Arthritis Rheum. 2010 Jun;62 (6):1583–1591.
2. Fernandez-Diaz C, Loricera J, Castañeda S, et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter of 63 patients. Semin Arthritis Rheum. 2018 Aug;48(1):22–27.
3. Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): A phase 2, randomized, controlled trial. Lancet. 2016 Jun 25;387:2630–2640.
4. Roodenrijs NMT, de Hair MJH, vander Goes MC, et al. Characteristics of difficult-to-treat rheumatoid arthritis: Results of an international survey. Ann Rheum Dis. 2018 Dec;77(12):1705–1709.
5. Nagy G, Roodenrija NM, Welsing PM, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2020 Oct 1;annrheumdis-2020-217344. [Epub ahead of print.]
6. Smolen JS, Landewé RMB, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):685–699.
7. Singh JA, Saag KG, Bridges Jr SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016 Jan;68(1):1–26.